Eli Lilly (LLY) Q3 2026 Earnings Call Transcript
On its third-quarter 2026 earnings call, Eli Lilly reported revenue growth of 39%, attributed to demand for its obesity drugs and strong international growth.
fool.com ·
Actifs pris en charge
Ouvrir Mo
Eli Lilly
Avant ouverture
1 424,48 $US
-sur la période sélectionnée
+15,09 $US (+1,07 %)depuis la clôture américaine
- Prix onchain
- -
- Prime / décote
- -
Mis à jour Référence
Écarts de prix avant frais et coûts d’exécution. Comparer les prix
Actualités
Eli Lilly 'Deserves' Stock Upside: Analyst
Benzinga reports Eli Lilly beat third-quarter estimates on Mounjaro and Zepbound growth, with 2026 revenue guidance rising to $92 billion.
benzinga.com ·
LLY Stock Hits Record as CEO Says Middle-Income Consumers Are Driving Pharma’s ‘Largest New Category Expansion’
Eli Lilly CEO David Ricks said middle-income consumers are driving what he called the largest new category expansion in pharma, according to Benzinga's report on the company's latest earnings.
benzinga.com ·
Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales
Eli Lilly raised its revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion, its third outlook increase this year, as quarterly sales climbed 39%.
qz.com ·
Eli Lilly in Charts: Q3 Mounjaro reaches $10.7B, Jardiance surges 64.5% Y/Y to $1.58B
Seeking Alpha reports Mounjaro sales reached $10.7B in the third quarter, while Jardiance rose 64.5% year over year to $1.58B.
seekingalpha.com ·
Token
- Token
- LLYc
- Actions par token
- 1.00000000 LLY
Obtenir Mo
Conservez-le dans Mo
Conservez LLYc dans un portefeuille intelligent Mo sur Base que vous contrôlez.
Déplacez-le vite
Envoyez LLYc à un autre utilisateur Mo sans frais, ou vers tout portefeuille compatible Base de manière quasi instantanée.